Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Insight Molecular Diagnostics' Accounts Payables rose 720.81% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 720.81%. This contributed to the annual value of $2.3 million for FY2024, which is 13913.96% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported Accounts Payables of $1.1 million as of Q3 2025, which was up 720.81% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Accounts Payables peaked at $5.3 million during Q1 2021, and registered a low of $908000.0 during Q1 2024.
  • Its 5-year average for Accounts Payables is $2.0 million, with a median of $1.9 million in 2021.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 7017.59% in 2023, then soared by 15099.12% in 2025.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Accounts Payables stood at $2.1 million in 2021, then decreased by 12.85% to $1.8 million in 2022, then crashed by 47.55% to $953000.0 in 2023, then surged by 139.14% to $2.3 million in 2024, then tumbled by 53.66% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.3 million for Q2 2025, and $2.3 million during Q1 2025.